100 doses of Ebola drug available: Sarepta CEO

Sarepta CEO ready with Ebola drug if requested
Sarepta CEO ready with Ebola drug if requested   

The company behind one of the most promising Ebola treatments has enough doses to handle about 100 patients, Sarepta Therapeutics CEO Chris Garabedian said Tuesday on CNBC

Shares of the pharmaceutical firm spiked in after-hours trading after news that the Centers for Disease Control confirmed the first U.S. case of Ebola in a male being treated in Dallas.

On "Fast Money," Garabedian said that its Ebola drug treatment shows about a 60 percent to 80 percent success rate in monkeys, whereas death would normally occur within eight to 12 days.

Read MoreFirst confirmed case of Ebola confirmed in the United States: CDC

CDC: Will identify contacts of US Ebola patient
CDC: Will identify contacts of US Ebola patient   

But he added that the company didn't have the resources to quickly increase production.

"Yes, we need more funding to take the drug materials that we have currently to convert that into upwards 100 more courses of therapy, or more," Garabedian said. "To be able to ramp up to the thousands of doses would require a larger investment and more time that could take upwards of a year or more to be able to generate enough courses to treat thousands of patients."

Garabedian said that the company has been in contact with health-care agencies.

"We have been communicating to all of the government agencies, the World Health Organization," he said. "We've had people at the table at every substantive discussion around how to manage this Ebola outbreak and have educated everybody who's interested in learning about our technology and the drug we have available.

Read MoreEbola: A closer look at this 'frightening disease'

"Everybody knows we're here. They know the drug we have, and we're waiting for that call."

Garabedian said that the company has yet to examine its expected costs.

"Obviously, at this point we've not discussed or negotiated any costs or transfer or procurement, so if we got a request to really prepare and ramp up larger volumes of drugs, we would need to determine those costs and what kind of revenues would need to come into the company for us to be able to do that," he said.